|
Oct 3
|
Eli Lilly’s Weight-Loss Drugs No Longer in Shortage. Bad News for Hims & Hers.
|
|
Oct 3
|
Weight-Loss Drugs Are Everywhere Now. How the GLP-1 Copycats Took Over.
|
|
Oct 2
|
European Equities Close Mostly Higher in Wednesday Trading; Euro Area Unemployment Unchanged in August
|
|
Oct 2
|
Novo Nordisk Is Still a Buy, Analysts Say. Slowing Growth for Ozempic and Wegovy Isn’t a Problem.
|
|
Oct 2
|
Weight loss drug breakthroughs, gene therapies, and more: 8 clinical trials to watch right now
|
|
Oct 1
|
Novo Nordisk (NVO) Stock Moves -0.89%: What You Should Know
|
|
Oct 1
|
Novo Nordisk has mitigation plans to minimize disruption from port strikes
|
|
Sep 30
|
Novo Nordisk (NVO) Poised for 23.3% Upside as Obesity Market Expands and Clinical Trials Impress
|
|
Sep 30
|
Is Novo Nordisk A/S (NYSE:NVO) The Top Global Stock To Buy Now?
|
|
Sep 29
|
'Stop Ripping Us Off' – Incredibly, Elon Musk And Bernie Sanders Seem To Agree On This One Thing – 'I Really Am With Bernie On This One'
|
|
Sep 28
|
15 Unhealthiest Countries in Europe
|
|
Sep 28
|
Success in This New Battleground Could Make Eli Lilly and Novo Nordisk Stock Absolutely Fly for Years
|
|
Sep 27
|
Novo Nordisk stock closes lower, analyst warns about Wegovy sales
|
|
Sep 27
|
Top Midday Stories: Bristol-Myers Squibb Gets FDA Approval for Schizophrenia Drug; Novo Nordisk Shares Drop After Analyst's Sales Concerns
|
|
Sep 27
|
PFE vs. NVO: Which Stock Is the Better Value Option?
|
|
Sep 27
|
Novo Nordisk Slips On Analyst Warning Of Weaker Wegovy Sales
|
|
Sep 27
|
Novo Nordisk Just Committed More Than $1.1 Billion to Make the Next Ozempic, but Is the Stock a Buy?
|
|
Sep 27
|
Novo Nordisk’s Wegovy-Fueled Gains Fading as Analyst Doubts Grow
|
|
Jul 29
|
Novo Nordisk (NVO) Surpasses Market Returns: Some Facts Worth Knowing
|
|
Jul 29
|
Wall Street is still jittery on GLP-1s
|